Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurocritical Care
Published in: Neurocritical Care 2/2010

01-04-2010 | Translational Research

CNS Immune Responses Following Experimental Stroke

Authors: Dannielle Zierath, Matthew Thullbery, Jessica Hadwin, J. Michael Gee, Anna Savos, Angela Kalil, Kyra J. Becker

Published in: Neurocritical Care | Issue 2/2010

Login to get access

Abstract

Background and purpose

Animals subjected to an inflammatory insult with lipopolysaccharide (LPS) at the time of stroke are predisposed to develop a detrimental autoimmune response to myelin basic protein (MBP). In this study, we sought to determine whether other inflammatory stimuli could similarly invoke central nervous system (CNS) autoimmunity and whether these detrimental autoimmune responses occurred to antigens other than MBP.

Methods

Male Lewis rats underwent 3 h middle cerebral artery occlusion (MCAO) and received intraperitoneal injections of LPS, staphylococcal enterotoxin B (SEB), lipoteichoic acid (LTA) or saline at the time of reperfusion. Behavioral tests were performed at set time intervals after MCAO and animals were sacrificed at 1 month to analyze the immune response to MBP, neuron specific enolase (NSE) and proteolipid protein (PLP).

Results

Lymphocytes from SEB treated animals were highly reactive to all tested CNS antigens, but treatment with LPS was most likely to lead to a Th1(+) response. A Th1(+) response to MBP, NSE or PLP in spleen was associated with worse outcome, although the response to NSE was most predictive of poor outcome. Animals with a cell mediated autoimmune response to either MBP or NSE in spleen had a concomitant humoral response to these antigens.

Conclusions

These data show that LPS, but not other inflammatory stimuli, increase the likelihood of developing a detrimental autoimmune response to an array of brain antigens.
Literature
1.
Netea MG, van der Graaf C, Van der Meer JW, Kullberg BJ. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol. 2004;75:749–55.CrossRefPubMed
2.
3.
Becker KJ, Kindrick DL, Lester MP, Shea C, Ye ZC. Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab. 2005;25:1634–44.CrossRefPubMed
4.
Kilic U, Kilic E, Matter CM, Bassetti CL, Hermann DM. TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiol Dis. 2008;31:33–40.CrossRefPubMed
5.
Caso JR, Pradillo JM, Hurtado O, Leza JC, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke. 2008;39:1314–20.CrossRefPubMed
6.
Cao CX, Yang QW, Lv FL, Cui J, Fu HB, Wang JZ. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun. 2007;353:509–14.CrossRefPubMed
7.
Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR. Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol. 2004;11:49–53.CrossRefPubMed
8.
Harms H, Prass K, Meisel C, et al. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS ONE. 2008;3:e2158.CrossRefPubMed
9.
Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.PubMed
10.
Huang W, Koller LD. Superantigen activation and kinetics of cytokines in the Long-Evans rat. Immunology. 1998;95:331–8.CrossRefPubMed
11.
Chatterjee PK, Zacharowski K, Cuzzocrea S, et al. Lipoteichoic acid from Staphylococcus aureus reduces renal ischemia/reperfusion injury. Kidney Int. 2002;62:1249–63.CrossRefPubMed
12.
Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–6.PubMed
13.
Hernandez TD, Schallert T. Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318–24.CrossRefPubMed
14.
Becker K, Kindrick D, McCarron R, Hallenbeck J, Winn R. Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: a role for lymphocytes in ischemic brain injury? Stroke. 2003;34:1809–15.CrossRefPubMed
15.
Becker KJ. Sensitization and tolerization to brain antigens in stroke. Neuroscience. 2009;158:1090–7.CrossRefPubMed
16.
17.
Toubi E, Shoenfeld Y. Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity. 2004;37:183–8.CrossRefPubMed
18.
Huang YH, Haegerstrand A, Frostegard J. Effects of in vitro hyperthermia on proliferative responses and lymphocyte activity. Clin Exp Immunol. 1996;103:61–6.CrossRefPubMed
19.
Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol. 1997;17:89–118.PubMed
20.
Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988;239:290–2.CrossRefPubMed
21.
Kato H, Kogure K, Liu XH, Araki T, Itoyama Y. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain Res. 1996;734:203–12.CrossRefPubMed
22.
Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994;180:631–40.CrossRefPubMed
23.
Jiang-Shieh YF, Yeh KY, Wei IH, et al. Responses of microglia in vitro to the gram-positive bacterial component, lipoteichoic acid. J Neurosci Res. 2005;82:515–24.CrossRefPubMed
24.
Lee SJ, Lee S. Toll-like receptors and inflammation in the CNS. Curr Drug Targets Inflamm Allergy. 2002;1:181–91.CrossRefPubMed
25.
Zanin-Zhorov A, Tal-Lapidot G, Cahalon L, et al. Cutting edge: T cells respond to lipopolysaccharide innately via TLR4 signaling. J Immunol. 2007;179:41–4.PubMed
26.
Manicassamy S, Ravindran R, Deng J, et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med. 2009;15:401–9.CrossRefPubMed
27.
Kerfoot SM, Long EM, Hickey MJ, et al. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol. 2004;173:7070–7.PubMed
28.
Kato N, Fujii Y, Agata N, et al. Experimental murine model for autoimmune myocarditis using Klebsiella pneumoniae O3 lipopolysaccharide as a potent immunological adjuvant. Autoimmunity. 1993;14:231–6.CrossRefPubMed
29.
Zaccone P, Fehervari Z, Blanchard L, Nicoletti F, Edwards CK 3rd, Cooke A. Autoimmune thyroid disease induced by thyroglobulin and lipopolysaccharide is inhibited by soluble TNF receptor type I. Eur J Immunol. 2002;32:1021–8.CrossRefPubMed
30.
31.
Friedman SM, Tumang JR, Crow MK. Microbial superantigens as etiopathogenic agents in autoimmunity. Rheum Dis Clin North Am. 1993;19:207–22.PubMed
32.
33.
34.
Gee JM, Kalil A, Thullbery M, Becker KJ. Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke. Stroke. 2008;39:1575–82.CrossRefPubMed
35.
Hofstetter HH, Targoni OS, Karulin AY, Forsthuber TG, Tary-Lehmann M, Lehmann PV. Does the frequency and avidity spectrum of the neuroantigen-specific T cells in the blood mirror the autoimmune process in the central nervous system of mice undergoing experimental allergic encephalomyelitis? J Immunol. 2005;174:4598–605.PubMed
36.
Muhallab S, Lidman O, Weissert R, Olsson T, Svenningsson A. Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2001;113:202–11.CrossRefPubMed
37.
Wang WZ, Olsson T, Kostulas V, Hojeberg B, Ekre HP, Link H. Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol. 1992;88:157–62.PubMedCrossRef
38.
Bornstein NM, Aronovich B, Korczyn AD, Shavit S, Michaelson DM, Chapman J. Antibodies to brain antigens following stroke. Neurology. 2001;56:529–30.PubMed
39.
Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49:1752–62.CrossRefPubMed
40.
Dale RC, Candler PM, Church AJ, Wait R, Pocock JM, Giovannoni G. Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol. 2006;172:187–97.CrossRefPubMed
41.
Fillit HM, Kemeny E, Luine V, Weksler ME, Zabriskie JB. Antivascular antibodies in the sera of patients with senile dementia of the Alzheimer’s type. J Gerontol. 1987;42:180–4.PubMed
42.
Jankovic BD, Horvat J, Djordjijevic D, Ramah A, Fridman V, Spahic O. Brain-associated autoimmune features in heroin addicts: correlation to HIV infection and dementia. Int J Neurosci. 1991;58:113–26.CrossRefPubMed
43.
Braus BK, Hauck SM, Amann B, et al. Neuron-specific enolase antibodies in patients with sudden acquired retinal degeneration syndrome. Vet Immunol Immunopathol. 2008;124:177–83.CrossRefPubMed
44.
Ikeda Y, Maruyama I, Nakazawa M, Ohguro H. Clinical significance of serum antibody against neuron-specific enolase in glaucoma patients. Jpn J Ophthalmol. 2002;46:13–7.CrossRefPubMed
45.
Jankovic BD, Djordjijevic D. Differential appearance of autoantibodies to human brain S100 protein, neuron specific enolase and myelin basic protein in psychiatric patients. Int J Neurosci. 1991;60:119–27.CrossRefPubMed
46.
Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am. 2009;29:247–64.CrossRefPubMed
47.
Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521–30.CrossRefPubMed
48.
Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and vascular injury. Trends Immunol. 2001;22:602–7.CrossRefPubMed
49.
Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci. 2000;20:RC87.PubMed
50.
Tarozzo G, Campanella M, Ghiani M, Bulfone A, Beltramo M. Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci. 2002;15:1663–8.CrossRefPubMed
51.
Soriano SG, Amaravadi LS, Wang YF, et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol. 2002;125:59–65.CrossRefPubMed
52.
Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008;28:1707–21.CrossRefPubMed
53.
Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol. 2003;137:210–7.CrossRefPubMed
54.
Matsunawa M, Isozaki T, Odai T, et al. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 2006;54:3408–16.CrossRefPubMed
55.
Yajima N, Kasama T, Isozaki T, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670–5.CrossRefPubMed
56.
Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001;107:1173–81.CrossRefPubMed
Metadata
Title
CNS Immune Responses Following Experimental Stroke
Authors
Dannielle Zierath
Matthew Thullbery
Jessica Hadwin
J. Michael Gee
Anna Savos
Angela Kalil
Kyra J. Becker
Publication date
01-04-2010
Publisher
Humana Press Inc
Published in
Neurocritical Care / Issue 2/2010
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-009-9270-4

Other articles of this Issue 2/2010

Neurocritical Care 2/2010 Go to the issue

Practical Pearl

CT Perfusion Evidence of Early Global Cerebral Hypoperfusion After Aneurysmal Subarachnoid Hemorrhage with Cardiac Arrest

Neuroimage

A Giant Bilateral Calcified Chronic Subdural Hematoma

Original Article

Prospective, Randomized, Single-Blinded Comparative Trial of Intravenous Levetiracetam Versus Phenytoin for Seizure Prophylaxis

Original Article

Moderate Hypoglycemia is Associated With Vasospasm, Cerebral Infarction, and 3-Month Disability After Subarachnoid Hemorrhage

Practical Pearl

Cerebral Vasospasm and Concurrent Left Ventricular Outflow Tract Obstruction: Requirement for Modification of Hyperdynamic Therapy Regimen

Original Article

Simultaneous Bedside Assessment of Global Cerebral Blood Flow and Effective Cerebral Perfusion Pressure in Patients with Intracranial Hypertension